
25 Feb 2021
Hikma Pharmaceuticals: Strong performance in FY20, upgrade to Buy
This content is only available within our institutional offering.

Sign in
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
This content is only available to commercial clients. Sign in if you have access or contact support@research-tree.com to set up a commercial account
Hikma Pharmaceuticals: Strong performance in FY20, upgrade to Buy
Hikma Pharmaceuticals Plc (HIK:LON) | 1,616 -194 (-0.7%) | Mkt Cap: 3,587m
- Published:
25 Feb 2021 -
Author:
Stefan Hamill | Paul Cuddon | Kane Slutzkin | Ceri Morgan -
Pages:
4 -